107 related articles for article (PubMed ID: 1311436)
1. Protection of cisplatin-induced neuropathy: recent developments.
Hamers F; Neijt J; Gispen W
Pathol Biol (Paris); 1992 Nov; 39(9):829-30. PubMed ID: 1311436
[No Abstract] [Full Text] [Related]
2. Pharmacological interventions to reduce platinum-induced toxicity.
Tognella S
Cancer Treat Rev; 1990 Sep; 17(2-3):139-42. PubMed ID: 2176930
[No Abstract] [Full Text] [Related]
3. Rationale for the use of the ACTH4-9 analogue ORG 2766 in the treatment of diabetic neuropathy.
Bravenboer B; Erkelens DW; Gispen WH
Neth J Med; 1992 Dec; 41(5-6):255-8. PubMed ID: 1337372
[No Abstract] [Full Text] [Related]
4. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
[TBL] [Abstract][Full Text] [Related]
5. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers J; Chaudhry V; Cavaletti G; Donehower R
Cochrane Database Syst Rev; 2007 Jan; (1):CD005228. PubMed ID: 17253547
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Gandara DR; Perez EA; Weibe V; De Gregorio MW
Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
[TBL] [Abstract][Full Text] [Related]
7. Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.
Hilkens PH; van der Burg ME; Moll JW; Planting AS; van Putten WL; Vecht CJ; van den Bent MJ
Eur J Cancer; 1995; 31A(5):678-81. PubMed ID: 7640038
[TBL] [Abstract][Full Text] [Related]
8. Effect of an ACTH(4-9) analogue on cisplatin neuropathy of longstanding duration: a phase II study.
Hilkens PH; van der Burg ME; Moll JW; van den Bent MJ; van Putten WL; Vecht CJ
Clin Neurol Neurosurg; 1995 May; 97(2):139-41. PubMed ID: 7656487
[TBL] [Abstract][Full Text] [Related]
9. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
10. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.
Hamers FP; Pette C; Bravenboer B; Vecht CJ; Neijt JP; Gispen WH
Cancer Chemother Pharmacol; 1993; 32(2):162-6. PubMed ID: 8387400
[TBL] [Abstract][Full Text] [Related]
12. A review of the use of chemoprotectants in cancer chemotherapy.
Lewis C
Drug Saf; 1994 Sep; 11(3):153-62. PubMed ID: 7811398
[TBL] [Abstract][Full Text] [Related]
13. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial.
van Gerven JM; Hovestadt A; Moll JW; Rodenburg CJ; Splinter TA; van Oosterom AT; Keizer L; Drogendijk TE; Groenhout CM; Vecht CJ
J Neurol; 1994 Jun; 241(7):432-5. PubMed ID: 7931444
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin neurotoxicity.
Mollman JE
N Engl J Med; 1990 Jan; 322(2):126-7. PubMed ID: 2152970
[No Abstract] [Full Text] [Related]
15. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.
Hovestadt A; van der Burg ME; Verbiest HB; van Putten WL; Vecht CJ
J Neurol; 1992 Mar; 239(3):143-6. PubMed ID: 1315383
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats.
Gerritsen van der Hoop R; de Koning P; Boven E; Neijt JP; Jennekens FG; Gispen WH
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):637-42. PubMed ID: 2838292
[TBL] [Abstract][Full Text] [Related]
17. [Glutathione chemoprotection therapy against CDDP-induced neurotoxicity in patients with invasive bladder cancer].
Sumiyoshi Y; Hashine K; Kasahara K; Karashima T
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1506-8. PubMed ID: 8854791
[TBL] [Abstract][Full Text] [Related]
18. Neurotrophic effects of ACTH/MSH neuropeptides.
de Wied D
Acta Neurobiol Exp (Wars); 1990; 50(4-5):353-66. PubMed ID: 1966658
[TBL] [Abstract][Full Text] [Related]
19. ACTH/MSH like peptides in the treatment of cisplatin neuropathy.
Gispen WH; Hamers FP; Vecht CJ; Jennekens FG; Neyt JP
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):179-83. PubMed ID: 1326318
[TBL] [Abstract][Full Text] [Related]
20. Administration of the cytoprotectant amifostine.
Lindemann K
Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
